Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

Oslo, 19 December 2024: Reference is made to the stock exchange notice published
by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated
business combination between the Company and Zelluna Immunotherapy AS and the
fully committed private placement.

The Company's board of directors (the "Board") hereby calls for an extraordinary
general meeting on 9 January 2025 at 09:00 CET (the "EGM") to resolve upon the
matters proposed by the Board in the attached EGM notice.

The EGM will be held electronically. For participation, please log in at
https://dnb.lumiagm.com/ with the user ID and password provided.

All documents and appendices regarding the EGM are made available at the
Company's website: www.ultimovacs.com (https://www.ultimovacs.com).

For further information, please see www.ultimovacs.com
(https://www.ultimovacs.com) or contact:

Hans Vassgård Eid, Interim CEO and CFO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632